Breast Cancer Clinical Trial
Official title:
Improving Survivorship Outcomes for African American and Latinx Cancer Survivors and Caregiver Dyads Through A Culturally Based Training Program for Underserved Health Professional Students
Verified date | July 2022 |
Source | Charles Drew University of Medicine and Science |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This proposed intervention centers on improving survivorship outcomes among African American and Latinx cancer survivor and caregiver dyads. As a result, there will be four major outcomes. First, as a result of partnership with minority social institutions (e.g. faith leaders), we will develop an in-depth culturally sensitive curriculum and survivorship care plan for Cancer Survivorship and Caregiver Leaders Aimed for Minority Populations (CSC LAMPs). Second, we will increase knowledge and skills by evaluating a comprehensive cancer survivorship training program designed for underserved health professional students. Third, the implementation of this program will improve survivorship outcomes among African American and Latinx cancer survivors with advanced stage cancer and their caregivers. Lastly, this study will build sustainability for underserved minorities with the training of 30 future healthcare providers as a valuable community resource for improving cancer survivorship outcomes. The long-term outcomes of the CSC LAMPs program will generate workforce capacity and diversity in cancer-based clinical practice, research, and community advocacy for underserved minority cancer survivors and caregivers.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Aim 1 Focus Group for Cancer Survivors and Caregivers: Inclusion Criteria - Individuals ages 18 and older - identify as African American or Latinx - identify as a cancer survivor and/or caregiver - speak and/or understand English Exclusion Criteria - individuals ages 17 years or younger - does not identify as African American or Latinx - unable to speak or understand English - does not identify as a cancer survivor or caregiver Aim 1 Focus Group for Oncology Healthcare Providers: Inclusion Criteria - Individuals ages 18 and older - identify as a healthcare provider - provide care to cancer patients in current provider role - speak and/or understand English Exclusion Criteria - individuals ages 17 years or younger - unable to speak or understand English - does not provide care to cancer patients - does not identify as a healthcare provider Aim 2: Inclusion Criteria - Individuals ages 18 and older - registered as a CDU student - speak and/or understand English - considered to be underserved, which include a) identifying as an underrepresented minority: Asian, Pacific Islander, African American, Hispanic, and Native American/Alaskan Native and/or b) from a medically underserved population (i.e. faced economic, cultural or linguistic barriers to health care) Exclusion Criteria - individuals ages 17 years or younger - not registered as a CDU student - unable to speak or understand English - not considered to be underserved For Aim 3: Inclusion Criteria - cancer survivor with a participating caregiver - stage III or stage IV cancer diagnosis - breast, lung, or colorectal cancer diagnosis - identify as African American or Latinx - speak and/or understand English Exclusion Criteria - individuals ages 17 years or younger - does not identify as African American or Latinx - unable to speak or understand English - does not identify as a cancer survivor - cancer survivor does not identify a caregiver - does not have a breast, lung, or colorectal cancer diagnosis - not diagnosed with a stage III or stage IV cancer diagnosis |
Country | Name | City | State |
---|---|---|---|
United States | Charles R. Drew University of Medicine & Science | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Charles Drew University of Medicine and Science |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Increase in psychosocial well-being using the Quality of Life: Short Form Health Survey and the Center for Epidemiologic Studies Depression Scale | By comparison from baseline to post-intervention, there will be a 25% increase in the psychosocial well-being among study participants. | 3 months | |
Primary | Reduction of barriers to symptom management Using the Symptom Distress Scale survey | By comparison from baseline to post-intervention, there will be a 25% decrease in the barriers to symptom management among study participants. | 3 months | |
Primary | 3. Decrease in unmet needs Using the Barriers to Follow-Up Care Survey and Cancer Survivors Unmet Needs instrument | By comparison from baseline to post-intervention, there will be a 25% decrease in the unmet needs among study participants. | 3 months | |
Primary | Reduction in caregiver burden using the Caregiver reaction assessment (CRA) survey | By comparison from baseline to post-intervention, there will be a 25% decrease in the caregiver burden among study participants. | 3 months | |
Primary | 5. Increase knowledge and utilization of supportive services using the Medical Outcomes Study Social Support Survey | By comparison from baseline to post-intervention, there will be a 25% increase in the knowledge and utilization of supportive services among study participants. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |